| Activeport Group Ltd (ATV) ORDINARY FULLY PAID |
Information Technology |
$30 |
ATV Completion of pro-rata entitlement issue
|
25 Aug 2025 6:48PM |
$0.019 |
$0.026 |
risen by
36.84%
|
|
ATV - Price-sensitive ASX Announcement
Full Release
Key Points
- Activeport Group Ltd announced the successful completion of its entitlement offer.
- The non-renounceable rights issue was announced on 4 August 2025 and closed on 22 August 2025.
- The 1 for 2.75 rights issue was priced at 1 cent per share to raise approximately $2.5 million.
- For every 2 new shares issued, eligible shareholders receive 1 free attaching new option.
- The new options have an exercise price of 2 cents and expire on 30 November 2028.
- The rights issue was fully underwritten by Alpine Capital Pty Ltd and GBA Capital Pty Ltd.
- New securities are scheduled to be issued on 29 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$210 |
Appendix 4G
|
25 Aug 2025 6:47PM |
$0.029 |
$0.066 |
risen by
131.58%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$210 |
Corporate Governance Statement
|
25 Aug 2025 6:46PM |
$0.029 |
$0.066 |
risen by
131.58%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$210 |
ACW FY2025 results - accelerating Alzheimers pivotal trial
|
25 Aug 2025 6:46PM |
$0.029 |
$0.066 |
risen by
131.58%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen released its FY2025 financial results.
- XanaMIA Phase 2b/3 Alzheimer’s trial reached 100 participants.
- Interim analysis of XanaMIA expected in January 2026.
- XanaCIDD Phase 2a depression trial showed significant benefits.
- Actinogen received $11.1m capital raising and $9m R&D tax rebate.
- Preparation for commercialization and regulatory discussions ongoing.
- A 15kg batch of Xanamem tablets produced for trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$210 |
ACW FY2025 results - accelerating Alzheimers pivotal trial
|
25 Aug 2025 6:46PM |
$0.029 |
$0.066 |
risen by
131.58%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited (ACW) released its FY2025 financial results, highlighting progress toward pivotal trial results for Alzheimer's disease.
- The XanaMIA Phase 2b/3 clinical trial for Alzheimer's disease surpassed the 100th participant milestone, with interim analysis in January 2026 and final results expected in Q4 2026.
- The XanaCIDD Phase 2a trial for major depressive disorder showed significant benefits on depression symptoms.
- Xanamem, the lead compound, is being developed to control brain cortisol levels and is investigated for Alzheimer's disease and depression.
- Actinogen completed an $11.1 million capital raising and received a $9 million R&D tax incentive rebate.
- The company conducted commercial readiness planning, including appointing a Chief Commercial Officer and securing a manufacturing scale-up.
- The FY2025 net loss was $14,732,263, primarily due to R&D expenses for clinical trials.
- Upcoming news includes interim data from the XanaMIA trial and potential FDA and EMA interactions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$210 |
ACW Appendix 4E and 2025 annual report
|
25 Aug 2025 6:42PM |
$0.029 |
$0.066 |
risen by
131.58%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical focuses on therapies for neurological diseases.
- The company reported a net loss of $14.7 million for FY2025.
- Revenue from ordinary activities increased by 135% to $685,253.
- Clinical trials for Xanamem, targeting Alzheimer's and Depression, are underway.
- The XanaMIA phase 2b/3 trial is a crucial part of their clinical program.
- Interim results for the Alzheimer's trial are expected in January 2026.
- Actinogen Medical is financially stable and actively pursuing strategic collaborations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$210 |
ACW Appendix 4E and 2025 annual report
|
25 Aug 2025 6:42PM |
$0.029 |
$0.066 |
risen by
131.58%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited's financial report covers the fiscal year ending 30 June 2025.
- The company had cash and cash equivalents totaling $15,718,435 at the end of the fiscal year.
- The total financial liabilities amounted to $1,498,495.
- Interest rate risk is managed by assessing potential changes in interest rates and their impact.
- The exercise of unlisted and listed options contributed to changes in issued shares.
- Various share issues and cancellations occurred during the year for both employee and director loan plans.
- Total current liabilities were $1,240,099, with non-current liabilities at $258,396.
- A sensitivity analysis model was used to assess the impact of interest rate fluctuations on profit/equity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,204 |
GYG Confirmation of Voluntary Escrow Release
|
25 Aug 2025 6:39PM |
$25.540 |
$21.580 |
fallen by
15.51%
|
|
| Platinum Asia Investments Limited (PAI) ORDINARY FULLY PAID |
Financials |
- |
Implementation of Scheme and Delisting
|
25 Aug 2025 6:36PM |
$0.970 |
$0.970 |
fallen by
0%
|
|
| New Frontier Minerals Limited (NFM) ORDINARY FULLY PAID |
Materials |
$31 |
Notification regarding unquoted securities - NFM
|
25 Aug 2025 6:34PM |
$0.013 |
$0.018 |
risen by
38.46%
|
|
| Flagship Minerals Limited (FLG) ORDINARY FULLY PAID |
Materials |
$72 |
Application for quotation of securities - FLG
|
25 Aug 2025 6:34PM |
$0.060 |
$0.240 |
risen by
300%
|
|
| Goodman Group (GMG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$63,021 |
30 June 2025 Distribution Taxation Components
|
25 Aug 2025 6:29PM |
$34.190 |
$30.820 |
fallen by
9.86%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$25 |
Change in substantial holding
|
25 Aug 2025 6:26PM |
$0.044 |
$0.050 |
risen by
13.64%
|
|
| Great Northern Minerals Limited (GNM) ORDINARY FULLY PAID |
Materials |
$22 |
Ceasing to be a substantial holder
|
25 Aug 2025 6:19PM |
$0.082 |
$0.045 |
fallen by
45.12%
|
|
| Step One Clothing Limited (STP) ORDINARY FULLY PAID |
Consumer Discretionary |
$62 |
Change of Director's Interest Notice - David Gallop
|
25 Aug 2025 6:12PM |
$0.570 |
$0.335 |
fallen by
41.23%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$13,252 |
Change in substantial holding
|
25 Aug 2025 6:11PM |
$31.800 |
$30.790 |
fallen by
3.18%
|
|
| Almonty Industries Inc (AII) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$104 |
Cleansing Statement
|
25 Aug 2025 6:10PM |
$6.620 |
$13.240 |
risen by
100%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$25 |
Cleansing Notice
|
25 Aug 2025 6:10PM |
$0.044 |
$0.050 |
risen by
13.64%
|
|
| Almonty Industries Inc (AII) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$104 |
Notification regarding unquoted securities - AII
|
25 Aug 2025 6:09PM |
$6.620 |
$13.240 |
risen by
100%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$25 |
Notification regarding unquoted securities - MAG
|
25 Aug 2025 6:08PM |
$0.044 |
$0.050 |
risen by
13.64%
|
|
| St Barbara Limited (SBM) ORDINARY FULLY PAID |
Materials |
$714 |
Change of Director's Interest Notice
|
25 Aug 2025 6:07PM |
$0.345 |
$0.590 |
risen by
71.01%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$25 |
Application for quotation of securities - MAG
|
25 Aug 2025 6:05PM |
$0.044 |
$0.050 |
risen by
13.64%
|
|
| Kingfisher Mining Ltd (KFM) ORDINARY FULLY PAID |
Materials |
$9 |
Date of AGM & Closing Date for Director Nominations
|
25 Aug 2025 6:03PM |
$0.053 |
$0.090 |
risen by
69.81%
|
|
| Beamtree Holdings Limited (BMT) ORDINARY FULLY PAID |
Health Care |
$64 |
Beamtree FY25 Results and Investor Webinar - Updated Link
|
25 Aug 2025 5:56PM |
$0.260 |
$0.220 |
fallen by
15.38%
|
|
| Supply Network Limited (SNL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,405 |
Appendix 4E and Annual Accounts June 2025
|
25 Aug 2025 5:52PM |
$41.140 |
$32.110 |
fallen by
21.95%
|
|
SNL - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after income tax increased to $40.023 million in 2025 from $33.025 million in 2024.
- Total revenue for 2025 was $349.9 million, up from $302.9 million in 2024.
- Supply Network Limited operates in the aftermarket parts sector for commercial vehicles, with main geographical segments in Australia and New Zealand.
- Dividends paid per share increased from $0.51 in 2024 to $0.65 in 2025.
- The company's shares are traded on the Australian Securities Exchange under the code SNL.
- Employee benefits expenses rose to $60.565 million in 2025 from $50.486 million in 2024.
- Net assets increased to $138.193 million in 2025 from $103.234 million in 2024.
- The company made significant investments in right-of-use assets, reflected in increased depreciation charges.
- Current liabilities increased to $60.368 million in 2025 from $53.664 million in 2024.
- The finance revenue for 2025 was $485,000, up from $142,000 in 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.